Journey Medical Corporation is a pharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes over seven branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products that have been approved by the United States Food and Drug Administration (FDA) for sale include Qbrexza, Accutane, Targadox, Ximino, and Exelderm Cream and Solution. The Company's product Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, which is an oral isotretinoin drug for the treatment of severe recalcitrant severe acne; Targadox, which is an oral doxycycline drug for adjunctive therapy for acne; Ximino, which is an oral minocycline drug for the treatment of moderate to severe acne, and Exelderm Cream and Solution is an antifungal intended for topical use.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)